Invech Holdings Files S-1/A Amendment

TL;DR

Invech Holdings (IVCH?) filed an S-1/A amendment. Looks like they're still working on their registration. Keep an eye on this one.

AI Summary

Invech Holdings, Inc. filed an S-1/A amendment on August 6, 2024, for its registration statement. The company, formerly known as Amersin Life Sciences CORP, HUBEI PHARMACEUTICAL GROUP LTD, and PAN ASIA COMMUNICATIONS CORP, is incorporated in Nevada and its principal executive offices are located in Scottsdale, AZ. The filing is related to SEC Act of 1933 and has SEC file number 333-276779.

Why It Matters

This S-1/A filing indicates ongoing regulatory activity and potential future stock offerings or changes for Invech Holdings, Inc., which could impact investors and market perception.

Risk Assessment

Risk Level: medium — S-1/A filings often precede significant corporate actions like stock offerings, which can introduce volatility and risk for investors.

Key Numbers

• 333-276779 — SEC File Number (Identifies the specific registration statement with the SEC.)
• 20240806 — Filing Date (Date the S-1/A amendment was filed with the SEC.)

Key Players & Entities

• Invech Holdings, Inc. (company) — Registrant
• Amersin Life Sciences CORP (company) — Former company name
• HUBEI PHARMACEUTICAL GROUP LTD (company) — Former company name
• PAN ASIA COMMUNICATIONS CORP (company) — Former company name
• Nevada (jurisdiction) — State of incorporation
• Scottsdale, AZ (location) — Principal executive offices address
• 333-276779 (filing_number) — SEC file number
• Pacific Stock Transfer Co. (company) — Agent for service
• Rhonda Keaveney (person) — Correspondence contact

FAQ

Key Financial Figures

• $25,000 — n of operations we require a minimum of $25,000 to maintain websites, email campaigns,
• $2,083 — Our monthly burn rate is approximately $2,083. As of this filing, the Company has run
• $29,617 — 024, the Company incurred a net loss of $29,617 and used cash of $29,617 for operating
• $63,092 — ompany had a working capital deficit of $63,092 and an accumulated deficit of $276,207.
• $276,207 — f $63,092 and an accumulated deficit of $276,207. During the year ended December 31, 2
• $64,641 — 023, the Company incurred a net loss of $64,641 and used cash of $63,641 for operating
• $63,641 — a net loss of $64,641 and used cash of $63,641 for operating activities. As of Decembe
• $33,641 — ompany had a working capital deficit of $33,641 and an accumulated deficit of $246,590.
• $246,590 — f $33,641 and an accumulated deficit of $246,590. These factors raise substantial doub
• $30,641 — mber 31, 2024, SCC advanced the Company $30,641 to pay for general operating expenses.
• $1,000 — services, for total non-cash expense of $1,000. During the year ended 2019, Robert C
• $4,443 — 2019, Robert Chin advanced the Company $4,443 to pay for general operating expenses.

Filing Documents

• invech_s1a8.htm (S-1/A) — 864KB
• 0001683168-24-005290.txt ( ) — 865KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING 15 DIVIDEND POLICY 15 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 16

USE OF PROCEEDS

USE OF PROCEEDS 16 DETERMINATION OF OFFERING PRICE 16

DILUTION

DILUTION 16 SELLING SECURITY HOLDERS 17 PLAN OF DISTRIBUTION-SELLING STOCKHOLDERS 22

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 25 LEGAL MATTERS 27 EXPERTS 27 INTERESTS OF NAMED EXPERTS AND COUNSEL 27 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 28 DESCRIPTION OF BUSINESS 37 MARKET FOR OUR COMMON STOCK 42 DIRECTORS AND EXECUTIVE OFFICERS 43

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 49 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 50

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL 52 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 53 WHERE YOU CAN FIND MORE INFORMATION 56 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus or contained in any prospectus supplement or free writing prospectus filed with the Securities and Exchange Commission (the “ SEC ”). Neither we nor the selling stockholders have authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the SEC. The selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: Neither we nor the selling stockholders have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. As used in this prospectus, unless otherwise designated, the terms “ we ,” “ us ,” “ our ,” the “ Company ,” “ IVHI ” and “ our Company ” refer to Invech Holdings, Inc., a Nevada corporation. ii CAUTION REGARDING FORWARD-LOOKING

SUMMARY INFORMATION, RISK FACTORS AND RATIO OF EARNINGS

ITEM 3. SUMMARY INFORMATION, RISK FACTORS AND RATIO OF EARNINGS TO FIXED CHARGES We and our business are subject to material risks, which could cause actual results, performance and achievements to differ materially from those anticipated, and the risk factors set forth in the section entitled “ Risk Factors ” beginning on page 6 of this prospectus. These risks can be summarized as follows: Business Related Risks · We have incurred operating losses in some of our historical periods and we could incur additional losses until we successfully integrate acquired practices, improve collections for procedures and reduce operating expenses. · Our capital resources may not be sufficient to meet our capital requirements, and in the absence of additional resources we may have to curtail or cease business operations. · We may encounter substantial competition in the public company compliance consulting industry and our failure to compete effectively may adversely affect our ability to generate revenue. · We may face a number of risks associated with our business services, including the possibility that we may incur substantial debt or convertible debt, which could adversely affect our financial condition. · Our development will depend on the efforts of key management, key personnel and our relationships with operators and other partnerships. · Our officers, directors and principal stockholders own a large percentage of our stock and other stockholders have little or no ability to elect directors or influence corporate matters. Risk Related to our Stock · Our stock trades on an unsolicited basis only, so you may be unable to sell your shares at or near the quoted bid prices if you need to sell a significant number of your shares. · Our common stock is defined as “penny stock” under the Exchange Act, and the rules promulgated thereunder. · We may issue more shares in an

View Full Filing

View this S-1/A filing on SEC EDGAR